GLP-1OCDReddit Obsessive-compulsive disorder (OCD) is a complex mental health condition characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions).作者：L Zhang·2025·被引用次数：2—Our study suggests that GLP-1RAs may decrease the risk of schizophrenia, anxiety disorders, bipolar disorder, bulimia nervosa, PTSD, and autism, ... While traditional treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) are foundational, research is increasingly exploring novel therapeutic avenues. Among these, peptides for OCD are emerging as a promising area of investigation, with researchers delving into how these small protein fragments might influence brain function and alleviate symptoms. This exploration is driven by a growing understanding of the neurobiological underpinnings of OCD and the potential for targeted peptide interventions.
Neuropeptides, which are short chains of amino acids, act as signaling molecules in the brain.Bottom line: Given the lack of evidence for benefit and the risk of side effects,thereis not enough evidence to recommend tryptophan and 5-HTP as treatments ... Evidence suggests that these signaling pathways may be implicated in the pathophysiology of OCD. For instance, studies have investigated the role of oxytocin, a neuropeptide associated with social bonding and stress regulation. Early research, such as a 1992 study on syntocinon (a synthetic form of oxytocin), explored its effects on patients with OCD2026年1月7日—GLP-1 receptor agonists have no established role in the treatment ofobsessive-compulsivedisorder and should not be used for this indication.. While some findings have been mixed, the investigation into oxytocin highlights the potential for neuropeptides to modulate mood and anxiety-related behaviors relevant to OCDObsessive-compulsive disorder (OCD) - Diagnosis and treatment. Beyond oxytocin, other neuropeptides are being examined for their influence on memory, learning, and emotional processing, all of which can be affected in individuals with OCD.
Several classes of peptides are drawing attention for their potential therapeutic applications in OCD. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs primarily known for diabetes management, have shown intriguing results. Liraglutide, a GLP-1 agonist, has been observed to reduce unwanted behaviors, potentially by mitigating repetitive, intrusive thoughts, particularly those related to food.Semi-synthetic polysaccharide with xylan and a new regenerative peptide.Rejuvenate the horse joints. Reduces pain, swelling, stiff joints and inflammation. While GLP-1 receptor agonists currently have no established role in OCD treatment, ongoing research aims to clarify their precise mechanisms and potential efficacy.
Another area of interest involves naturally occurring peptides and their derivatives. For example, research has explored the effects of CCK-tetrapeptide, though some studies suggest it may not play a significant role in the pathophysiology of OCD. Conversely, the concept of peptide therapy more broadly is being considered a promising modality for OCD, leveraging the potent biological properties of these molecules. This includes the investigation of substances like Multi Collagen Peptides, which are being explored in the context of overall health and potentially mood regulationA New Treatment for OCD Found In Antibodies.
While peptides represent an exciting frontier, the treatment landscape for OCD is multifaceted. Research into new treatments includes the development of antibodies that target specific proteins, such as Immuno-moodulin (Imood), which has shown potential in reducing anxiety levels. Similarly, identifying novel neural biomarkers for OCD is paving the way for more targeted interventions, including deep brain stimulation (DBS) for severe, treatment-resistant cases.
Nutritional and herbal supplements, alongside other compounds, are also part of the broader investigational scope.AI-Designed Drug Enters Phase I to Treat OCD While some, like N-acetylcysteine (NAC), are recognized for their potential to alleviate compulsive behaviors, others, such as tryptophan and 5-HTP, have shown insufficient evidence of benefit and carry risksBottom line: Given the lack of evidence for benefit and the risk of side effects,thereis not enough evidence to recommend tryptophan and 5-HTP as treatments .... Amino acids like gamma-aminobutyric acid (GABA) are also explored due to their role in brain function and potential to be lower in individuals with OCDFunctional Medicine for OCD.
The exploration of peptides for OCD signifies a dynamic evolution in understanding and treating this challenging disorder. While neuropeptides like oxytocin and peptide classes such as GLP-1 receptor agonists are subjects of ongoing research, they represent just one facet of a larger, integrated approach.作者：A Järvinen·2019·被引用次数：31—Liraglutide treatment reduced weight and unwanted behaviorseemingly by preventing food-related repetitive thoughts and compulsions. The development of antibody-based therapies, the identification of biomarkers, and the continued investigation into supplements and other compounds all contribute to a growing arsenal of potential treatments. As scientific understanding deepens, the hope is for more personalized and effective interventions that can significantly improve the lives of individuals living with OCD.Obsessive-compulsive disorder (OCD) - Diagnosis and treatment
Join the newsletter to receive news, updates, new products and freebies in your inbox.